41,660 Shares in Exelixis, Inc. $EXEL Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 41,660 shares of the biotechnology company’s stock, valued at approximately $2,267,000.

Other institutional investors have also bought and sold shares of the company. Motiv8 Investments LLC bought a new position in shares of Exelixis in the 4th quarter worth about $26,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Exelixis during the 1st quarter valued at about $27,000. Western Wealth Management LLC bought a new stake in shares of Exelixis during the 1st quarter valued at about $29,000. Acumen Wealth Advisors LLC acquired a new stake in Exelixis during the fourth quarter worth approximately $29,000. Finally, Activest Wealth Management acquired a new stake in Exelixis during the fourth quarter worth approximately $32,000. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $56.72 on Wednesday. The business’s 50 day simple moving average is $54.38 and its two-hundred day simple moving average is $48.79. The firm has a market cap of $14.05 billion, a P/E ratio of 17.84, a PEG ratio of 1.63 and a beta of 0.44. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $57.57.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. On average, equities analysts forecast that Exelixis, Inc. will post 3.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, Director Jack L. Wyszomierski sold 3,925 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $50.55, for a total transaction of $198,408.75. Following the transaction, the director owned 284,384 shares in the company, valued at approximately $14,375,611.20. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary C. Beckerle sold 9,812 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares in the company, valued at $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 23,549 shares of company stock worth $1,216,894 in the last ninety days. Corporate insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EXEL. Citizens Jmp boosted their price target on Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a research note on Wednesday, June 24th. Barclays raised their price objective on shares of Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 14th. Leerink Partners lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 price objective for the company. in a research note on Thursday, August 6th. Citigroup reiterated a “market outperform” rating on shares of Exelixis in a research report on Wednesday, July 22nd. Finally, Zacks Research cut shares of Exelixis from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Exelixis currently has a consensus rating of “Hold” and a consensus price target of $50.07.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.